RATIO-LISINOPRIL P TABLET

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

LISINOPRIL

Beschikbaar vanaf:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATC-code:

C09AA03

INN (Algemene Internationale Benaming):

LISINOPRIL

Dosering:

20MG

farmaceutische vorm:

TABLET

Samenstelling:

LISINOPRIL 20MG

Toedieningsweg:

ORAL

Eenheden in pakket:

100/500

Prescription-type:

Prescription

Therapeutisch gebied:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0121550002; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2014-09-19

Productkenmerken

_ _
_ratio-LISINOPRIL P 5 mg, 10 mg and 20 mg Tablets _
_Page 1 of 37_
PRODUCT MONOGRAPH
RATIO-LISINOPRIL P
Lisinopril
Tablets 5 mg, 10 mg and 20 mg
USP
Angiotensin Converting Enzyme Inhibitor
ratiopharm inc.
Canada J7J 1P3
Date of Preparation:
August 31, 2007
Control Number: 081736, 109658
_ _
_ratio-LISINOPRIL P 5 mg, 10 mg and 20 mg Tablets _
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
14
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND
ADMINISTRATION.............................................................................
15
OVERDOSAGE
...............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND
STABILITY.........................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 20
PART II: SCIENTIFIC INFORMATION
..............................................................................
21
PHARMACEUTICAL
INFORMATION.........................................................................
21
CLINICAL
TRIALS.............